Table 2 Secondary outcomes
Adverse effects | Number of studies (Reference no.) | Patients in Sugammadex group (Incidence, %) | Patients in Control group (Incidence, %) | I2 (%) | Risk ratio with [95% CI] | P value |
|---|---|---|---|---|---|---|
PONV | 13 (23,25,28,29,32–40) | 33/431 (7.66%) | 69/393 (17.56%) | 21 | 0.30 [0.20, 0.46] |  < 0.00001* |
Bradycardia | 4 (25,26,33,40) | 0/124 (0%) | 15/122 (12.30%) | 0 | 0.09 [0.02, 0.46] | 0.004* |
Pain | 2 (23,39) | 8/67 (11.94%) | 5/31 (16.13%) | 0 | 1.21 [0.46, 3.17] | 0.70 |
Bronchospasm/ Laryngospasm | 3 (25,28,34) | 1/114 (0.88%) | 4/112 (3.57%) | 0 | 0.45 [0.10, 1.96] | 0.29 |
Dry mouth | 2 (33,35) | 3/60 (5%) | 25/60 (41.67%) | 0 | 0.14 [0.05, 0.38] | 0.0001* |
Apnea | 2 (34,40) | 0/65 (0%) | 2/65 (3.08%) | 0 | 0.33 [0.04, 3.12] | 0.34 |
Oxygen desaturation | 3 (34,35,38) | 3/95 (3.16%) | 8/95 (8.42%) | 0 | 0.41 [0.12, 1.37] | 0.15 |